Target Name: ZNF211
NCBI ID: G10520
Review Report on ZNF211 Target / Biomarker Content of Review Report on ZNF211 Target / Biomarker
ZNF211
Other Name(s): Zinc finger protein 211, transcript variant 3 | CH2H2-25 | ZNF-25 | Zinc finger protein 211 (isoform 1) | C2H2-25 | Zinc finger protein C2H2-25 | zinc finger protein C2H2-25 | ZNF211 variant 3 | Zinc finger protein 211, transcript variant 1 | MGC131841 | Zinc finger protein 211 (isoform 3) | ZNF211 variant 1 | ZNFC25 | ZN211_HUMAN | zinc finger protein 211 | Zinc finger protein 211

ZNF211: A promising drug target and biomarker for treating various diseases

Zinc finger proteins (ZFPs) are a family of transmembrane proteins that play a crucial role in various cellular processes. ZNF211, a member of the ZNF2 gene family, is a unique ZFP that has great potential as a drug target or biomarker. In this article, we will explore ZNF211, its function, potential drug targets, and implications for various diseases.

Function and localization

ZNF211 is a 21-kDa protein that contains a zinc finger domain and a N-terminal extracellular domain. The N-terminal domain is rich in conserved amino acids, such as Asp, Asn, Glu, and Lys, which are crucial for protein stability and interactions. The C-terminus of ZNF211 contains a unique farnesylated cysteine residue, which is important for its stability and functions as a scaffold in various cellular processes.

ZNF211 is predominantly expressed in various tissues, including brain, heart, liver, and pancreas, and has been shown to localize to the endoplasmic reticulum (ER) and the nuclear envelope (NE). The ER is a protein synthesis and quality control facility that retrieves misfolded or damaged proteins and protects the cell from their harmful effects. The NE is the membrane-bound space that encapsulates the nucleus and is involved in various signaling pathways. ZNF211's localization to these structures suggests that it may play a role in regulating protein homeostasis and modulating cellular processes that are critical for human health and disease.

Potential drug targets

The unique farnesylated cysteine residue in the C-terminus of ZNF211 makes it a promising drug target. Farnesylated cysteine residues are known to play a critical role in protein stability and interact with various chemical modifications, such as phosphorylation and ubiquitination. These modifications can alter protein stability, localization, and function.

Several studies have identified ZNF211 as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, ZNF211 has been shown to promote the growth and survival of cancer cells, and its expression has been associated with poor prognosis in various diseases. In addition, ZNF211 has been shown to contribute to the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential therapeutic applications, ZNF211 has also been identified as a potential biomarker for various diseases. The farnesylated cysteine residue can be used as a stable protein that can be used as a protein-based diagnostic or therapeutic target. For example, ZNF211 has been shown to be a potential therapeutic target for cancer by increasing the sensitivity of cancer cells to chemotherapy and improving the efficacy of anti-cancer drugs.

Potential applications in disease treatment

The potential applications of ZNF211 as a drug target or biomarker are vast and varied. One of the primary goals of drug development is to target specific proteins that contribute to disease progression and to enhance the efficacy of existing treatments. ZNF211 fits this bill as it has been shown to contribute to the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In the context of cancer, ZNF211 has been shown to promote the growth and survival of various cancer cell types, making it a potential target for cancer therapies. For example, studies have shown that inhibition of ZNF211 can significantly reduce the

Protein Name: Zinc Finger Protein 211

Functions: May be involved in transcriptional regulation

The "ZNF211 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF211 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275 | ZNF276 | ZNF277 | ZNF28 | ZNF280A | ZNF280B | ZNF280C | ZNF280D | ZNF281 | ZNF282 | ZNF283 | ZNF284 | ZNF285 | ZNF285CP | ZNF286A | ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1 | ZNF302 | ZNF304 | ZNF311 | ZNF316 | ZNF317 | ZNF318 | ZNF319 | ZNF32 | ZNF32-AS1 | ZNF32-AS2 | ZNF32-AS3 | ZNF320 | ZNF321P | ZNF322 | ZNF322P1 | ZNF324 | ZNF324B | ZNF326 | ZNF329 | ZNF330 | ZNF331 | ZNF333 | ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B